$13.900.00 (0.00%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
Organon (OGN) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 2.9% in FY25, net margin 3.0%, and free cash flow (~$538.0M) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($M)▼2.9%
6,216.0
FY21→FY25CAGR −0.4%/yr
Net income ($M)▼78.4%
187.0
one-off year: see footnoteCAGR −39.0%/yr
Free cash flow ($M)▼29.6%
538.0
FY21→FY25CAGR −27.7%/yr
Diluted EPS▼78.4%
0.72
FY21→FY25CAGR −39.3%/yr
What the receipts whisper · what a headline number hides
Share count
+2.6%
254.2mn → 260.8mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
Capex
$162.0M
steady at 2.6% of revenue (−7.4% YoY).
Returns vs FCF
16%
$88.0M returned vs $538.0M of FCF in FY25. Buybacks + dividends covered by cash flow.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
3¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 61.9% → 53.3%. Net margin 3.0% is below the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 6,099.0 | 6,216.0 | 6,403.0 | 6,263.0 | 6,174.0 | 6,304.0 | ▼2.9% | −0.4% |
Cost of revenue | 2,859.0 | 2,903.0 | 2,688.0 | 2,515.0 | 2,294.0 | 2,399.0 | ▲8.0% | +4.9% |
Gross profit | 3,240.0 | 3,313.0 | 3,715.0 | 3,748.0 | 3,880.0 | 3,905.0 | ▼10.8% | −4.0% |
Research & development | 358.0 | 372.0 | 550.0 | 536.0 | 578.0 | 443.0 | ▼32.4% | −4.3% |
Selling, general & admin | 1,712.0 | 1,721.0 | 1,760.0 | 1,893.0 | 1,704.0 | 1,668.0 | ▼2.2% | +0.8% |
Total operating expenses | 2,409.0 | 2,489.0 | 2,341.0 | 2,491.0 | 2,310.0 | 2,114.0 | ▲6.3% | +4.2% |
Operating incomefeeds ROC rank | 831.0 | 824.0 | 1,374.0 | 1,257.0 | 1,570.0 | 1,791.0 | ▼40.0% | −17.6% |
Other income, net | −328.0 | −399.0 | −567.0 | −584.0 | −448.0 | −262.0 | — | — |
Pretax income | 503.0 | 425.0 | 807.0 | 673.0 | 1,122.0 | 1,529.0 | ▼47.3% | −27.4% |
Income tax | 290.0 | 238.0 | −57.0 | −350.0 | 205.0 | 178.0 | — | +7.5% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 213.0 | 187.0 | 864.0 | 1,023.0 | 917.0 | 1,351.0 | ▼78.4% | −39.0% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 0.77 | 0.72 | 3.33 | 3.99 | 3.59 | 5.31 | ▼78.4% | −39.3% |
Diluted shares (mn) | 272.38 | 260.76 | 259.15 | 256.27 | 255.17 | 254.19 | ▲0.6% | +0.6% |
| Margins | ||||||||
Gross margin32nd pct in Healthcare | 53.1% | 53.3% | 58.0% | 59.8% | 62.8% | 61.9% | ▼4.7pp | −8.6pp |
Operating margin | 13.6% | 13.3% | 21.5% | 20.1% | 25.4% | 28.4% | ▼8.2pp | −15.2pp |
Net margin50th pct in Healthcare | 3.5% | 3.0% | 13.5% | 16.3% | 14.9% | 21.4% | ▼10.5pp | −18.4pp |
† TTM = trailing four quarters through 2026-09-30.FY23 effective tax rate was −52% vs a 12% norm for this window, likely a one-time item; see the filing.FY24 effective tax rate was −7% vs a 12% norm for this window, likely a one-time item; see the filing.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Organon's revenue last fiscal year?
Organon reported revenue of $6,216.0M in fiscal 2025, down 2.9% from fiscal 2024.
What was Organon's net income?
Organon reported net income of $187.0M in fiscal 2025, a net margin of 3.0%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

